3,4-dihydroxyphenylacetic acid has been researched along with Parkinsonian Disorders in 95 studies
3,4-Dihydroxyphenylacetic Acid: A deaminated metabolite of LEVODOPA.
(3,4-dihydroxyphenyl)acetic acid : A dihydroxyphenylacetic acid having the two hydroxy substituents located at the 3- and 4-positions. It is a metabolite of dopamine.
dihydroxyphenylacetic acid : A dihydroxy monocarboxylic acid consisting of phenylacetic acid having two phenolic hydroxy substituents.
Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Oral administration of 10% solution of Phytomix-40 (multicomponent plant phytoadaptogen) to C57Bl/6 mice with MPTP-induced Parkinson's syndrome alleviated symptoms (oligokinesia and muscle rigidity), compensated for the deficiency of dopamine and its metabolites (DOPAC and homovanillic acid), and reduced the level of lipid peroxides in the striatum." | 3.73 | Effect of complex phytoadaptogen on MPTP-induced Parkinson's syndrome in mice. ( Belorustseva, SA; Bocharov, EV; Bocharova, OA; Kryzhanovskii, GN; Kucheryanu, VG; Kudrin, VS, 2006) |
| "In a model of early-stage Parkinson's disease induced by a single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to Wistar rats, a neuroprotective effect of a new derivative of carnosine and α-lipoic acid (C/LA nanomicellar complex) was demonstrated." | 1.48 | Neuroprotective effect of the carnosine - α-lipoic acid nanomicellar complex in a model of early-stage Parkinson's disease. ( Berezhnoy, DS; Fedorova, TN; Kulikova, OI; Lopachev, AV; Orlova, VS; Stvolinsky, SL, 2018) |
| "Lactacystin is a selective UPS inhibitor recently used to destroy dopamine (DA) neurons in animal models of Parkinson's disease (PD)." | 1.42 | Decreased behavioral response to intranigrally administered GABAA agonist muscimol in the lactacystin model of Parkinson's disease may result from partial lesion of nigral non-dopamine neurons: comparison to the classical neurotoxin 6-OHDA. ( Czarnecka, A; Kamińska, K; Konieczny, J; Lenda, T; Nowak, P, 2015) |
| " Behavioral deficits at the end of the 14-day dosing regime and on day 28 (i." | 1.40 | Intranasal administration of alpha-synuclein aggregates: a Parkinson's disease model with behavioral and neurochemical correlates. ( Davydova, TV; Fomina, VG; Gruden, MA; Kudrin, VS; Morozova-Roche, LA; Narkevich, VB; Sewell, RD; Wang, C, 2014) |
| "Parkinson's disease and pure autonomic failure involve differential dopaminergic versus noradrenergic lesions." | 1.38 | Cerebrospinal fluid biomarkers of central catecholamine deficiency in Parkinson's disease and other synucleinopathies. ( Goldstein, DS; Holmes, C; Sharabi, Y, 2012) |
| " Long recovery periods after MPP(+) exposure are required to distinguish between reversible or irreversible toxic and/or trophic effects." | 1.33 | Characterization of organotypic ventral mesencephalic cultures from embryonic mice and protection against MPP toxicity by GDNF. ( Gramsbergen, JB; Jakobsen, B; Møller Dall, A; Rosenblad, C; Zimmer, J, 2005) |
| "(1) Caffeine treatment produced a dose-dependent attenuation of MPTP-induced striatal dopamine loss in both young and retired breeder (RB) male, but not female, mice." | 1.33 | Estrogen prevents neuroprotection by caffeine in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. ( Ascherio, A; Brown-Jermyn, D; Chen, JF; Dluzen, DE; Schwarzschild, MA; Xu, K; Xu, Y, 2006) |
| " Therefore, the aim of the present study was to examine whether the long-term administration of a commonly used herbicide, paraquat, which has already been found to induce a slowly progressing degeneration of the nigrostriatal neurons, influences mesocortical dopaminergic neurons in rats." | 1.33 | Degeneration of dopaminergic mesocortical neurons and activation of compensatory processes induced by a long-term paraquat administration in rats: implications for Parkinson's disease. ( Biedka, I; Bortel, A; Dabrowska, J; Kuter, K; Nowak, P; Ossowska, K; Rommelspacher, H; Schulze, G; Smiałowska, M; Wardas, J; Wierońska, J; Zieba, B, 2006) |
| " Estrogen altered the toxic effects of the second invasion of MA as indicated by a significant decrease in striatal dopamine (DA) and 3,4-dihydroxyphenylacetic acid (DOPAC) concentrations." | 1.33 | Effect of estrogen upon methamphetamine-induced neurotoxicity within the impaired nigrostriatal dopaminergic system. ( Dluzen, DE; Liu, B, 2006) |
| "Behaviour was evaluated by catalepsy tests and activity box." | 1.32 | Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of substantia nigra in rats. ( Schmidt, WJ; Srinivasan, J, 2003) |
| "Tolcapone treatment enhanced CSF DOPAC concentrations in unlesioned animals (by approximately four times) as well as monkeys rendered parkinsonian after severe nigrostriatal dopaminergic injury caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)." | 1.32 | Cerebrospinal fluid 3,4-dihydroxyphenylacetic acid level after tolcapone administration as an indicator of nigrostriatal degeneration. ( Di Monte, DA; Langston, JW; Thiffault, C, 2003) |
| " In addition, chronic GDNF treatment did not induce the side-effects generally associated with chronic administration of levodopa, the most widely used treatment for Parkinson's disease." | 1.31 | Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. ( Andersen, AH; Cass, WA; Elsberry, DD; Gash, DM; Gerhardt, GA; Grondin, R; Klein, MC; Maswood, N; Yi, A; Zhang, Z, 2002) |
| "Melatonin was initially dissolved in dimethyl sulfoxide (DMSO), diluted to 16 microg/ml and then provided in the drinking water for 4 weeks." | 1.31 | Chronic administration of pharmacological levels of melatonin does not ameliorate the MPTP-induced degeneration of the nigrostriatal pathway. ( Morgan, WW; Nelson, JF, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (2.11) | 18.2507 |
| 2000's | 66 (69.47) | 29.6817 |
| 2010's | 26 (27.37) | 24.3611 |
| 2020's | 1 (1.05) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, YB | 1 |
| Wang, YQ | 1 |
| Wu, JR | 1 |
| Cui, YL | 1 |
| Celorrio, M | 1 |
| Rojo-Bustamante, E | 1 |
| Fernández-Suárez, D | 1 |
| Sáez, E | 1 |
| Estella-Hermoso de Mendoza, A | 1 |
| Müller, CE | 1 |
| Ramírez, MJ | 1 |
| Oyarzábal, J | 1 |
| Franco, R | 1 |
| Aymerich, MS | 1 |
| Ren, M | 1 |
| Guo, Y | 1 |
| Wei, X | 1 |
| Yan, S | 1 |
| Qin, Y | 1 |
| Zhang, X | 1 |
| Jiang, F | 1 |
| Lou, H | 1 |
| Kulikova, OI | 1 |
| Berezhnoy, DS | 1 |
| Stvolinsky, SL | 1 |
| Lopachev, AV | 1 |
| Orlova, VS | 1 |
| Fedorova, TN | 1 |
| Bhurtel, S | 1 |
| Katila, N | 1 |
| Srivastav, S | 1 |
| Neupane, S | 1 |
| Choi, DY | 1 |
| Delli Pizzi, S | 1 |
| Rossi, C | 1 |
| Di Matteo, V | 1 |
| Esposito, E | 1 |
| Guarnieri, S | 1 |
| Mariggiò, MA | 1 |
| Franciotti, R | 1 |
| Caulo, M | 1 |
| Thomas, A | 1 |
| Onofrj, M | 1 |
| Tartaro, A | 1 |
| Bonanni, L | 1 |
| Martin, HL | 1 |
| Mounsey, RB | 1 |
| Sathe, K | 1 |
| Mustafa, S | 1 |
| Nelson, MC | 1 |
| Evans, RM | 1 |
| Teismann, P | 3 |
| Stuckenholz, V | 1 |
| Bacher, M | 1 |
| Balzer-Geldsetzer, M | 1 |
| Alvarez-Fischer, D | 1 |
| Oertel, WH | 1 |
| Dodel, RC | 1 |
| Noelker, C | 1 |
| Gruden, MA | 1 |
| Davydova, TV | 1 |
| Narkevich, VB | 1 |
| Fomina, VG | 1 |
| Wang, C | 1 |
| Kudrin, VS | 2 |
| Morozova-Roche, LA | 1 |
| Sewell, RD | 1 |
| Oeckl, P | 1 |
| Scheffold, A | 1 |
| Lechel, A | 1 |
| Rudolph, KL | 1 |
| Ferger, B | 3 |
| Morin, N | 1 |
| Morissette, M | 1 |
| Grégoire, L | 1 |
| Di Paolo, T | 1 |
| Masoud, ST | 1 |
| Vecchio, LM | 1 |
| Bergeron, Y | 1 |
| Hossain, MM | 1 |
| Nguyen, LT | 1 |
| Bermejo, MK | 1 |
| Kile, B | 1 |
| Sotnikova, TD | 1 |
| Siesser, WB | 1 |
| Gainetdinov, RR | 1 |
| Wightman, RM | 1 |
| Caron, MG | 1 |
| Richardson, JR | 1 |
| Miller, GW | 3 |
| Ramsey, AJ | 1 |
| Cyr, M | 1 |
| Salahpour, A | 1 |
| Konieczny, J | 2 |
| Czarnecka, A | 2 |
| Kamińska, K | 1 |
| Lenda, T | 2 |
| Nowak, P | 3 |
| Bentea, E | 1 |
| Sconce, MD | 1 |
| Churchill, MJ | 1 |
| Van Liefferinge, J | 1 |
| Sato, H | 1 |
| Meshul, CK | 1 |
| Massie, A | 1 |
| Lei, P | 1 |
| Ayton, S | 1 |
| Appukuttan, AT | 1 |
| Volitakis, I | 1 |
| Adlard, PA | 1 |
| Finkelstein, DI | 1 |
| Bush, AI | 1 |
| Dupre, KB | 1 |
| Eskow, KL | 1 |
| Steiniger, A | 1 |
| Klioueva, A | 1 |
| Negron, GE | 1 |
| Lormand, L | 1 |
| Park, JY | 1 |
| Bishop, C | 1 |
| Anderson, DW | 1 |
| Bradbury, KA | 1 |
| Schneider, JS | 1 |
| Boulet, S | 1 |
| Mounayar, S | 1 |
| Poupard, A | 1 |
| Bertrand, A | 1 |
| Jan, C | 1 |
| Pessiglione, M | 1 |
| Hirsch, EC | 2 |
| Feuerstein, C | 1 |
| François, C | 1 |
| Féger, J | 1 |
| Savasta, M | 1 |
| Tremblay, L | 1 |
| Cheng, B | 1 |
| Yang, X | 1 |
| An, L | 1 |
| Gao, B | 1 |
| Liu, X | 1 |
| Liu, S | 1 |
| RajaSankar, S | 1 |
| Manivasagam, T | 1 |
| Sankar, V | 1 |
| Prakash, S | 1 |
| Muthusamy, R | 1 |
| Krishnamurti, A | 1 |
| Surendran, S | 1 |
| Kostrzewa, RA | 1 |
| Skaba, D | 1 |
| Kostrzewa, RM | 1 |
| Korkmaz, OT | 1 |
| Tunçel, N | 1 |
| Tunçel, M | 1 |
| Oncü, EM | 1 |
| Sahintürk, V | 1 |
| Celik, M | 1 |
| Chung, CY | 1 |
| Koprich, JB | 1 |
| Hallett, PJ | 1 |
| Isacson, O | 1 |
| Reksidler, AB | 1 |
| Lima, MM | 1 |
| Dombrowski, PA | 1 |
| Barnabé, GF | 1 |
| Andersen, ML | 1 |
| Tufik, S | 1 |
| Vital, MA | 1 |
| Kuroiwa, H | 1 |
| Yokoyama, H | 2 |
| Kimoto, H | 2 |
| Kato, H | 6 |
| Araki, T | 7 |
| Borah, A | 1 |
| Mohanakumar, KP | 1 |
| Bergstrom, BP | 1 |
| Sanberg, SG | 1 |
| Andersson, M | 1 |
| Mithyantha, J | 1 |
| Carroll, FI | 1 |
| Garris, PA | 1 |
| Gołembiowska, K | 1 |
| Dziubina, A | 1 |
| Chao, OY | 2 |
| Huston, JP | 3 |
| von Bothmer, A | 1 |
| Pum, ME | 2 |
| Shchepinov, MS | 1 |
| Chou, VP | 1 |
| Pollock, E | 1 |
| Langston, JW | 3 |
| Cantor, CR | 1 |
| Molinari, RJ | 1 |
| Manning-Boğ, AB | 2 |
| Mattern, C | 1 |
| Silva, AM | 1 |
| Wessler, J | 1 |
| Ruocco, LA | 1 |
| Nikolaus, S | 1 |
| Goldstein, DS | 2 |
| Holmes, C | 2 |
| Sharabi, Y | 2 |
| Sullivan, P | 1 |
| Cooney, A | 1 |
| Jinsmaa, Y | 1 |
| Sullivan, R | 1 |
| Gross, DJ | 1 |
| Kopin, IJ | 1 |
| McCormack, AL | 1 |
| Thiruchelvam, M | 1 |
| Thiffault, C | 2 |
| Cory-Slechta, DA | 1 |
| Di Monte, DA | 2 |
| Meissner, W | 2 |
| Harnack, D | 2 |
| Paul, G | 2 |
| Reum, T | 2 |
| Sohr, R | 2 |
| Morgenstern, R | 2 |
| Kupsch, A | 2 |
| Tillerson, JL | 2 |
| Cohen, AD | 1 |
| Caudle, WM | 2 |
| Zigmond, MJ | 1 |
| Schallert, T | 1 |
| Breidert, T | 1 |
| Callebert, J | 1 |
| Heneka, MT | 1 |
| Landreth, G | 1 |
| Launay, JM | 1 |
| Grondin, R | 1 |
| Zhang, Z | 1 |
| Yi, A | 1 |
| Cass, WA | 1 |
| Maswood, N | 1 |
| Andersen, AH | 1 |
| Elsberry, DD | 1 |
| Klein, MC | 1 |
| Gerhardt, GA | 1 |
| Gash, DM | 1 |
| Ricaurte, GA | 1 |
| Yuan, J | 1 |
| Hatzidimitriou, G | 1 |
| Cord, BJ | 1 |
| McCann, UD | 1 |
| Kurosaki, R | 1 |
| Muramatsu, Y | 2 |
| Michimata, M | 1 |
| Matsubara, M | 3 |
| Imai, Y | 5 |
| Itoyama, Y | 3 |
| Reverón, ME | 1 |
| Datla, KP | 1 |
| Murray, HE | 1 |
| Pillai, AV | 1 |
| Gillies, GE | 1 |
| Dexter, DT | 1 |
| Zafar, KS | 1 |
| Siddiqui, A | 1 |
| Sayeed, I | 1 |
| Ahmad, M | 1 |
| Salim, S | 1 |
| Islam, F | 1 |
| Archer, T | 1 |
| Fredriksson, A | 1 |
| Takahashi, A | 1 |
| Schlüter, OM | 1 |
| Fornai, F | 1 |
| Alessandrí, MG | 1 |
| Takamori, S | 1 |
| Geppert, M | 1 |
| Jahn, R | 1 |
| Südhof, TC | 1 |
| Shimizu, K | 1 |
| Matsubara, K | 1 |
| Ohtaki, K | 1 |
| Fujimaru, S | 1 |
| Saito, O | 1 |
| Shiono, H | 1 |
| Srinivasan, J | 1 |
| Schmidt, WJ | 1 |
| Chaturvedi, RK | 4 |
| Agrawal, AK | 4 |
| Seth, K | 4 |
| Shukla, S | 4 |
| Chauhan, S | 2 |
| Shukla, Y | 2 |
| Sinha, C | 2 |
| Seth, PK | 3 |
| Srivastava, N | 1 |
| Khanna, VK | 1 |
| Vaglini, F | 1 |
| Pardini, C | 1 |
| Viaggi, C | 1 |
| Bartoli, C | 1 |
| Dinucci, D | 1 |
| Corsini, GU | 1 |
| Ahmad, A | 1 |
| Shen, YQ | 1 |
| Hebert, G | 1 |
| Su, Y | 1 |
| Moze, E | 1 |
| Neveu, PJ | 1 |
| Li, KS | 1 |
| Lau, YS | 1 |
| Novikova, L | 1 |
| Roels, C | 1 |
| Jakobsen, B | 1 |
| Gramsbergen, JB | 1 |
| Møller Dall, A | 1 |
| Rosenblad, C | 1 |
| Zimmer, J | 1 |
| Xu, K | 2 |
| Xu, Y | 1 |
| Brown-Jermyn, D | 1 |
| Chen, JF | 2 |
| Ascherio, A | 1 |
| Dluzen, DE | 2 |
| Schwarzschild, MA | 2 |
| Oida, Y | 1 |
| Kitaichi, K | 1 |
| Nakayama, H | 1 |
| Ito, Y | 1 |
| Fujimoto, Y | 1 |
| Shimazawa, M | 1 |
| Nagai, H | 1 |
| Hara, H | 1 |
| Meuer, K | 1 |
| Pitzer, C | 1 |
| Krüger, C | 1 |
| Göricke, B | 1 |
| Laage, R | 1 |
| Lingor, P | 1 |
| Peters, K | 1 |
| Schlachetzki, JC | 1 |
| Kobayashi, K | 1 |
| Dietz, GP | 1 |
| Weber, D | 1 |
| Schäbitz, WR | 1 |
| Bach, A | 1 |
| Schulz, JB | 2 |
| Bähr, M | 1 |
| Schneider, A | 1 |
| Weishaupt, JH | 1 |
| Ossowska, K | 1 |
| Smiałowska, M | 1 |
| Kuter, K | 1 |
| Wierońska, J | 1 |
| Zieba, B | 1 |
| Wardas, J | 1 |
| Dabrowska, J | 1 |
| Bortel, A | 1 |
| Biedka, I | 1 |
| Schulze, G | 1 |
| Rommelspacher, H | 1 |
| Liu, B | 1 |
| Sava, V | 1 |
| Reunova, O | 1 |
| Velasquez, A | 1 |
| Sanchez-Ramos, J | 1 |
| Mohanasundari, M | 1 |
| Srinivasan, MS | 1 |
| Sethupathy, S | 1 |
| Sabesan, M | 1 |
| Enna, SJ | 1 |
| Reisman, SA | 1 |
| Stanford, JA | 1 |
| Mazzulli, JR | 1 |
| Mishizen, AJ | 1 |
| Giasson, BI | 1 |
| Lynch, DR | 1 |
| Thomas, SA | 1 |
| Nakashima, A | 1 |
| Nagatsu, T | 2 |
| Ota, A | 1 |
| Ischiropoulos, H | 1 |
| Bocharov, EV | 1 |
| Kucheryanu, VG | 1 |
| Kryzhanovskii, GN | 1 |
| Bocharova, OA | 1 |
| Belorustseva, SA | 1 |
| Hwang, YS | 1 |
| Shim, I | 1 |
| Lee, BB | 1 |
| Chang, JW | 1 |
| Megyeri, K | 1 |
| Marko, B | 1 |
| Sziray, N | 1 |
| Gacsalyi, I | 1 |
| Juranyi, Z | 1 |
| Levay, G | 1 |
| Harsing, LG | 1 |
| Jackson-Lewis, V | 1 |
| Przedborski, S | 1 |
| Sawada, H | 1 |
| Hishida, R | 1 |
| Hirata, Y | 1 |
| Ono, K | 1 |
| Suzuki, H | 1 |
| Muramatsu, S | 1 |
| Nakano, I | 1 |
| Sawada, M | 1 |
| Struve, MF | 1 |
| McManus, BE | 1 |
| Wong, BA | 1 |
| Dorman, DC | 1 |
| Inoue, H | 1 |
| Kataoka, A | 1 |
| Hua-Qin, W | 1 |
| Masuda, M | 1 |
| Ikeda, T | 1 |
| Tsukita, K | 1 |
| Soda, M | 1 |
| Kodama, T | 1 |
| Fuwa, T | 1 |
| Honda, Y | 1 |
| Kaneko, S | 1 |
| Matsumoto, S | 1 |
| Wakamatsu, K | 1 |
| Ito, S | 1 |
| Miura, M | 1 |
| Aosaki, T | 1 |
| Itohara, S | 1 |
| Takahashi, R | 1 |
| Liu, LX | 1 |
| Chen, WF | 1 |
| Xie, JX | 1 |
| Wong, MS | 1 |
| Takagi, S | 1 |
| Watanabe, Y | 1 |
| Sarre, S | 1 |
| Lanza, M | 1 |
| Makovec, F | 1 |
| Artusi, R | 1 |
| Caselli, G | 1 |
| Michotte, Y | 1 |
| Kadoguchi, N | 1 |
| Yano, R | 1 |
| Cintra, A | 1 |
| Aguirre, JA | 1 |
| Andbjer, B | 1 |
| Finnman, UB | 1 |
| Hagman, M | 1 |
| Agnati, LF | 1 |
| Höglund, C | 1 |
| Möller, A | 1 |
| Fuxe, K | 1 |
| Youdim, MB | 1 |
| Grünblatt, E | 1 |
| Mandel, S | 1 |
| Xue, YL | 1 |
| Wang, ZF | 1 |
| Zhong, DG | 1 |
| Cui, X | 1 |
| Li, XJ | 1 |
| Ma, XJ | 1 |
| Wang, LN | 1 |
| Zhu, K | 1 |
| Sun, AM | 1 |
| Hofele, K | 1 |
| Sedelis, M | 1 |
| Auburger, GW | 1 |
| Morgan, S | 1 |
| Schwarting, RK | 1 |
| Chekhonin, VP | 2 |
| Baklaushev, VP | 2 |
| Kogan, BM | 2 |
| Savchenko, EA | 2 |
| Lebedev, SV | 2 |
| Man'kovskaya, IV | 2 |
| Filatova, TS | 2 |
| Yusupova, IU | 1 |
| Dmitrieva, TB | 2 |
| Tariq, M | 1 |
| Khan, HA | 1 |
| Al Moutaery, K | 1 |
| Al Deeb, S | 1 |
| Lazarenko, IP | 1 |
| Belopasov, VV | 1 |
| Bezard, E | 1 |
| Ravenscroft, P | 1 |
| Gross, CE | 1 |
| Crossman, AR | 1 |
| Brotchie, JM | 1 |
| Gerlach, M | 1 |
| Xiao, AY | 1 |
| Kuhn, W | 1 |
| Lehnfeld, R | 1 |
| Waldmeier, P | 1 |
| Sontag, KH | 1 |
| Riederer, P | 1 |
| Petzer, JP | 1 |
| Staal, R | 1 |
| Xu, YH | 1 |
| Beilstein, M | 1 |
| Sonsalla, PK | 1 |
| Castagnoli, K | 1 |
| Castagnoli, N | 1 |
| Rathke-Hartlieb, S | 1 |
| Kahle, PJ | 1 |
| Neumann, M | 1 |
| Ozmen, L | 1 |
| Haid, S | 1 |
| Okochi, M | 1 |
| Haass, C | 1 |
| Tanaka, K | 2 |
| Abe, K | 1 |
| Taguchi, K | 1 |
| Wasai, T | 1 |
| Ren, J | 1 |
| Utsunomiya, I | 1 |
| Shinohara, T | 1 |
| Miyatake, T | 1 |
| Sano, T | 1 |
| Kumagai, T | 1 |
| Morgan, WW | 1 |
| Nelson, JF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Starving for Energy - A Pilot Study to Test Ketone Derived Energy in Eating Disorders[NCT05507008] | 40 participants (Anticipated) | Interventional | 2022-10-13 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
95 other studies available for 3,4-dihydroxyphenylacetic acid and Parkinsonian Disorders
| Article | Year |
|---|---|
A novel idea for establishing Parkinson's disease mouse model by intranasal administration of paraquat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Administration, Intranasal; Animals; Corpus Striatum; Disease Models | 2021 |
GPR55: A therapeutic target for Parkinson's disease?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson | 2017 |
TREM2 overexpression attenuates neuroinflammation and protects dopaminergic neurons in experimental models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Adenoviridae; Animals; | 2018 |
Neuroprotective effect of the carnosine - α-lipoic acid nanomicellar complex in a model of early-stage Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antioxidants; Brain; Carnosine; Dopamine; Homovanillic Acid | 2018 |
Mechanistic comparison between MPTP and rotenone neurotoxicity in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Astrocytes; Brain; Dopamine; Male; Mice, Inbred C57BL; MPTP | 2019 |
Morphological and metabolic changes in the nigro-striatal pathway of synthetic proteasome inhibitor (PSI)-treated rats: a MRI and MRS study.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Magnetic | 2013 |
A peroxisome proliferator-activated receptor-δ agonist provides neuroprotection in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cell Count; Cells, Cultured; Disease Models, Animal; Dopami | 2013 |
The α7 nAChR agonist PNU-282987 reduces inflammation and MPTP-induced nigral dopaminergic cell loss in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benzamides; Bridged Bicyclo Compounds; Calcium-Binding Prot | 2013 |
Intranasal administration of alpha-synuclein aggregates: a Parkinson's disease model with behavioral and neurochemical correlates.
Topics: 3,4-Dihydroxyphenylacetic Acid; Administration, Intranasal; alpha-Synuclein; Amyloid; Animals; Corpu | 2014 |
Substantial telomere shortening in the substantia nigra of telomerase-deficient mice does not increase susceptibility to MPTP-induced dopamine depletion.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 2014 |
Effect of a chronic treatment with an mGlu5 receptor antagonist on brain serotonin markers in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Benserazide; | 2015 |
Increased expression of the dopamine transporter leads to loss of dopamine neurons, oxidative stress and l-DOPA reversible motor deficits.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Anti-Dyskinesia Agents; Cell Death; Cytosol; Dopamine; Dopa | 2015 |
Decreased behavioral response to intranigrally administered GABAA agonist muscimol in the lactacystin model of Parkinson's disease may result from partial lesion of nigral non-dopamine neurons: comparison to the classical neurotoxin 6-OHDA.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcysteine; Animals; Cell Count; Corpus Striatum; Dopamine; Dose | 2015 |
MPTP-induced parkinsonism in mice alters striatal and nigral xCT expression but is unaffected by the genetic loss of xCT.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Amino Acid Transport S | 2015 |
Clioquinol rescues Parkinsonism and dementia phenotypes of the tau knockout mouse.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Clioquinol; Dementia; Disease Models, Animal; Dopami | 2015 |
Early increase in dopamine release in the ipsilateral striatum after unilateral intranigral administration of lactacystin produces spontaneous contralateral rotations in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcysteine; Amphetamine; Animals; Benzazepines; Central Nervous | 2016 |
Effects of coincident 5-HT1A receptor stimulation and NMDA receptor antagonism on L-DOPA-induced dyskinesia and rotational behaviors in the hemi-parkinsonian rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Corpus Striatum; Di | 2008 |
Broad neuroprotective profile of nicotinamide in different mouse models of MPTP-induced parkinsonism.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Humans; | 2008 |
Behavioral recovery in MPTP-treated monkeys: neurochemical mechanisms studied by intrastriatal microdialysis.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Chlorocebus aethiops; Corpus Striatum; Di | 2008 |
Ketogenic diet protects dopaminergic neurons against 6-OHDA neurotoxicity via up-regulating glutathione in a rat model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Brain; Brain Chemistry; Chromatography, | 2009 |
Withania somnifera root extract improves catecholamines and physiological abnormalities seen in a Parkinson's disease model mouse.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Disease Models, Animal; Dopamine; Glutathione; Glutathione | 2009 |
Acute L: -DOPA effect on hydroxyl radical- and DOPAC-levels in striatal microdialysates of parkinsonian rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Anim | 2010 |
Vasoactive intestinal peptide (VIP) treatment of Parkinsonian rats increases thalamic gamma-aminobutyric acid (GABA) levels and alters the release of nerve growth factor (NGF) by mast cells.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Female; gamma-Aminobutyric Acid; Heparin; Male; Mast Cells; | 2010 |
Functional enhancement and protection of dopaminergic terminals by RAB3B overexpression.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cell Line; Corpus Striatum; Dopamine; Female; Gene Expressi | 2009 |
Distinct effects of intranigral L-DOPA infusion in the MPTP rat model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; | 2009 |
Biochemical alterations of the striatum in an MPTP-treated mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Biomarkers; C | 2010 |
Salicylic acid protects against chronic L-DOPA-induced 6-OHDA generation in experimental model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 2010 |
Functional reorganization of the presynaptic dopaminergic terminal in parkinsonism.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Analysis of Variance; Animals; Chromatography, Hi | 2011 |
Effect of adenosine A(2A) receptor antagonists and L-DOPA on hydroxyl radical, glutamate and dopamine in the striatum of 6-OHDA-treated rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Animals; Benserazide; Caffeine; D | 2012 |
Chronic progesterone treatment of male rats with unilateral 6-hydroxydopamine lesion of the dorsal striatum exacerbates [corrected] parkinsonian symptoms.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Res | 2011 |
Isotopic reinforcement of essential polyunsaturated fatty acids diminishes nigrostriatal degeneration in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; alpha-Linolenic Acid; | 2011 |
Intranasally applied L-DOPA alleviates parkinsonian symptoms in rats with unilateral nigro-striatal 6-OHDA lesions.
Topics: 3,4-Dihydroxyphenylacetic Acid; Administration, Intranasal; Amphetamine; Analysis of Variance; Anima | 2012 |
Cerebrospinal fluid biomarkers of central catecholamine deficiency in Parkinson's disease and other synucleinopathies.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Biomarkers; Catecholamines; Dopamine Agents; Female; Fluorodeo | 2012 |
Vesicular uptake blockade generates the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 cells: relevance to the pathogenesis of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cytoplasmic Vesicles; Dopamine; Neurons; Parkinsonian Disor | 2012 |
Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Biomarkers; Dopamine; Environm | 2002 |
Deep brain stimulation of subthalamic neurons increases striatal dopamine metabolism and induces contralateral circling in freely moving 6-hydroxydopamine-lesioned rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cell Death; Disease Models, Animal; Dopamine; Electric Stim | 2002 |
Forced nonuse in unilateral parkinsonian rats exacerbates injury.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Behavior, Animal; Brain Chemistry; Casts, Surg | 2002 |
Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Administration, Oral; | 2002 |
Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemistry; Corpus Striatum; Dopamine; Drug Administra | 2002 |
RETRACTED: Severe dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA ("ecstasy").
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Autoradiography; Axons; Brain; Carrier Proteins; Corpus Str | 2002 |
Role of nitric oxide synthase against MPTP neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Astrocytes; C | 2002 |
Detection of behavioral impairments correlated to neurochemical deficits in mice treated with moderate doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Age Factors; Animals; Antiparkinson Agents; Behavior, Animal; Corpus | 2002 |
Differences in dopaminergic neuroprotective effects of estrogen during estrous cycle.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Chlorides; Diestrus; Dopamine; Dopamine Plasma Membrane Tra | 2003 |
Dose-dependent protective effect of selenium in rat model of Parkinson's disease: neurobehavioral and neurochemical evidences.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antioxidants; Ascorbic Acid; Behavior, Animal; Brain; Disea | 2003 |
An antihypokinesic action of alpha2-adrenoceptors upon MPTP-induced behaviour deficits in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Clonidine; Dopamine; Dopamine Agonists; Drug I | 2003 |
Protection of dopaminergic neurons with a novel astrocyte modulating agent (R)-(-)-2-propyloctanoic acid (ONO-2506) in an MPTP-mouse model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Astrocytes; Caprylates; Corpus Striatum; Disease Models, An | 2003 |
Role of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Uptake Inhibitors; alpha-Synuclein; Animals; Antibodies; | 2003 |
Paraquat induces long-lasting dopamine overflow through the excitotoxic pathway in the striatum of freely moving rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dizocilpine Maleate; Dopamine; Dopamine Pl | 2003 |
Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of substantia nigra in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Behavior, Animal; Benzylamines; Cataleps | 2003 |
Cerebrospinal fluid 3,4-dihydroxyphenylacetic acid level after tolcapone administration as an indicator of nigrostriatal degeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson | 2003 |
Effect of glial cell line-derived neurotrophic factor (GDNF) co-transplantation with fetal ventral mesencephalic cells (VMC) on functional restoration in 6-hydroxydopamine (6-OHDA) lesioned rat model of Parkinson's disease: neurobehavioral, neurochemical
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cell Line; Chemotherapy, Adjuvant; Female; Glial Cell Line- | 2003 |
Co-transplantation of carotid body and ventral mesencephalic cells as an alternative approach towards functional restoration in 6-hydroxydopamine-lesioned rats: implications for Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Binding, Competitive; Brain Tissue Transplantation; Carotid | 2004 |
Involvement of cytochrome P450 2E1 in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Allyl Compounds; Anima | 2004 |
Restorative potential of dopaminergic grafts in presence of antioxidants in rat model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antioxidants; Ascorbic Acid; Brain Tissue Transplantation; | 2004 |
In mice, production of plasma IL-1 and IL-6 in response to MPTP is related to behavioral lateralization.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Corpus | 2005 |
MPTP treatment in mice does not transmit and cause Parkinsonian neurotoxicity in non-treated cagemates through close contact.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Apoptosis; Bl | 2005 |
Characterization of organotypic ventral mesencephalic cultures from embryonic mice and protection against MPP toxicity by GDNF.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Cell Differentiation; Cell Pro | 2005 |
Estrogen prevents neuroprotection by caffeine in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Age Factors; Animals; Caffeine; Corpus Striatum; Cytochrome P-450 CY | 2006 |
Rifampicin attenuates the MPTP-induced neurotoxicity in mouse brain.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; | 2006 |
Granulocyte-colony stimulating factor is neuroprotective in a model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Blotting, Nor | 2006 |
Degeneration of dopaminergic mesocortical neurons and activation of compensatory processes induced by a long-term paraquat administration in rats: implications for Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Cerebral Cortex; Chromatography, High Pre | 2006 |
Effect of estrogen upon methamphetamine-induced neurotoxicity within the impaired nigrostriatal dopaminergic system.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Uptake Inhibitors; Animals; Corpus Striatum; Disease Mode | 2006 |
Can low level exposure to ochratoxin-A cause parkinsonism?
Topics: 3,4-Dihydroxyphenylacetic Acid; Age Factors; Age of Onset; Animals; Antioxidants; Carcinogens; Corpu | 2006 |
Enhanced neuroprotective effect by combination of bromocriptine and Hypericum perforatum extract against MPTP-induced neurotoxicity in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Ataxia; Bromocriptine; Catalase; Corp | 2006 |
CGP 56999A, a GABA(B) receptor antagonist, enhances expression of brain-derived neurotrophic factor and attenuates dopamine depletion in the rat corpus striatum following a 6-hydroxydopamine lesion of the nigrostriatal pathway.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain-Derived Neurotrophic Factor; Corpus Striatum; Denerva | 2006 |
Cytosolic catechols inhibit alpha-synuclein aggregation and facilitate the formation of intracellular soluble oligomeric intermediates.
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Amino Acid Substitution; Animals; Catechols; Cell D | 2006 |
Effect of complex phytoadaptogen on MPTP-induced Parkinson's syndrome in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Chromatography, High Pressure Liquid; Corpus Striatum; Dopa | 2006 |
Effect of subthalamic nucleus lesions in a 6-hydroxydopamine-induced rat parkinsonian model: behavioral and biochemical studies.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dominance, Cerebral; Dopamine; Globus Pall | 2006 |
Effects of 2,3-benzodiazepine AMPA receptor antagonists on dopamine turnover in the striatum of rats with experimental parkinsonism.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Benzodiazepines; Corpus Striatum; Dop | 2007 |
Protocol for the MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Disease Model | 2007 |
Activated microglia affect the nigro-striatal dopamine neurons differently in neonatal and aged mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Aging; Animals; Animal | 2007 |
Basal ganglia neurotransmitter concentrations in rhesus monkeys following subchronic manganese sulfate inhalation.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Basal Ganglia; Disease Models, Animal; Dopamine; gamma-Amin | 2007 |
Pael receptor is involved in dopamine metabolism in the nigrostriatal system.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 2007 |
Neuroprotective effects of genistein on dopaminergic neurons in the mice model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 2008 |
Role of reactive nitrogen and reactive oxygen species against MPTP neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Cytoprotectio | 2008 |
Zuckerkandl's organ improves long-term survival and function of neural stem cell derived dopaminergic neurons in Parkinsonian rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Bromodeoxyuridine; Cell Differentiation; Coculture Techniqu | 2008 |
In vivo neurochemical effects of the NR2B selective NMDA receptor antagonist CR 3394 in 6-hydroxydopamine lesioned rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adamantane; Amidines; Animals; Antiparkinson Agents; Basal Ganglia; | 2008 |
Failure of acute administration with proteasome inhibitor to provide a model of Parkinson's disease in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 2008 |
Subchronic toluene exposure in low concentrations produces signs of reduced dysfunction in the 6-hydroxydopamine lesioned nigrostriatal dopaminergic system of the rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Behavior, Animal; Denervation; Dopamine; Injec | 1999 |
The pivotal role of iron in NF-kappa B activation and nigrostriatal dopaminergic neurodegeneration. Prospects for neuroprotection in Parkinson's disease with iron chelators.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Ani | 1999 |
Xenotransplantation of microencapsulated bovine chromaffin cells into hemiparkinsonian monkeys.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenal Medulla; Animals; Antiparkinson Agents; Apomorphine; Capsule | 2000 |
Evidence for a dissociation between MPTP toxicity and tyrosinase activity based on congenic mouse strain susceptibility.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Ani | 2001 |
Catecholamines and their metabolites in the brain and urine of rats with experimental Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Catecholamines; Dihydroxyphenylalanine; Dopamine; Ep | 2000 |
Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Anti-Inflammatory Agents, Non- | 2001 |
Protective effect of quinacrine on striatal dopamine levels in 6-OHDA and MPTP models of Parkinsonism in rodents.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemistry; Dopamine; Enzyme Inhibitors; Glutathione; | 2001 |
Complex analysis of efficiency of transplantation of embryonic nerve tissue to rats with hemiparkinsonism.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Tissue Transplantation; Dopamine; Fetal Tissue Transp | 2000 |
Upregulation of striatal preproenkephalin gene expression occurs before the appearance of parkinsonian signs in 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine monkeys.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Dopamine; Enkephalins; Female; Gene Expression Regulation; | 2001 |
The central catechol-O-methyltransferase inhibitor tolcapone increases striatal hydroxyl radical production in L-DOPA/carbidopa treated rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O- | 2001 |
Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Caffeine; Cat | 2001 |
Striatal dopaminergic metabolism is increased by deep brain stimulation of the subthalamic nucleus in 6-hydroxydopamine lesioned rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Dopamine; Electric Stimulation Therapy; Extracellular Space | 2001 |
Sensitivity to MPTP is not increased in Parkinson's disease-associated mutant alpha-synuclein transgenic mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Amino | 2001 |
Riluzole (2-amino-6-trifluoromethoxy benzothiazole) attenuates MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Astrocytes; D | 2001 |
Stereoselective effect of (R)- and (S)-1-methyl-1,2,3,4-tetrahydroisoquinolines on a mouse model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Carbidopa; Cell Count; Disease Models, Animal; Dopamine; Do | 2001 |
Neuroprotective effect of riluzole in MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Dizocilpine M | 2001 |
Chronic administration of pharmacological levels of melatonin does not ameliorate the MPTP-induced degeneration of the nigrostriatal pathway.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Catecholamine | 2001 |